ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

32847 results sorted by trial registration date.
  • Improving patient's recall of past events through the use of technology

    Patient reported outcomes (PRO) are increasingly used to measure the effectiveness of interventions for management of chronic conditions. Many of these instruments require respondents to describe the change in their health status from baseline to a follow-up assessment. This is often problematic for patients with chronic disease and poor recall of previous health status limits the usefulness and validity of these PRO measures. The aim of the study proposed here is to evaluate the utility of tablet computers as a technological tool to aid patients’ recall of previous responses when completing PRO measures. Our hypothesis is that the magnitude of the difference (responsiveness) will be greatest in those who saw the audio-visual recording. The feasibility assessment will be reported using descriptive statistics based on the NIHR (UK) feasibility and pilot studies criteria..

  • A randomised control trial of the Uprise online program for university students

    The aim of this research project is to test an online program, Uprise, in Australian tertiary students. The program is designed to improve the wellbeing of university students through a series of interactive modules informed by cognitive behavioural therapy and mindfulness. Participation involves completing four modules of the program over a 4-week period. The study also involves at least three 2-4 hour assessments, one before starting the program, one after completion of the program, and another 3 months later. All assessment sessions will be held at the Swinburne Hawthorn campus, or via telephone or video conference. Half of the participants will be randomly selected to wait a month after the first assessment and complete an additional 1-2 hour assessment before starting the program.

  • Exploring the use of a non-pharmaceutical method to treat drooling in Parkinson's disease

    This study will explore the feasibility of expiratory muscle strength training (EMST), as a novel, non-invasive treatment approach to reduce drooling in people who have Parkinson's disease (PD). The intervention involves breathing into a threshold loading device. The intervention will take place over a 6 week period and will involve both supervised and unsupervised practice. We hypothesise that EMST will be feasible and well tolerated in this population and will reduce drooling in people with PD by strengthening the muscles associated with lip closure and swallowing.

  • Single Session Treatment for Specific Phobias in Pre-School Aged Children

    This study aims to treat young children between the ages of 3-5 years who are suffering from a specific phobia. Research to date suggests that whilst older children and adults can be successfully treated with a one session psychological treatment for phobias, it is currently unknown whether pre-school aged children will benefit and have long lasting effects from this intervention. The aim of this study is to engage children in a one session exposure treatment using a play based approach, and compare long term outcomes, relative to two other conditions -- a 6 month waitlist condition (monitoring only), as well as an education support intervention. This study is a randomized controlled trial, which means children are randomly assigned to one of three different conditions. The three conditions are; (1) a one-session cognitive-behavioural intervention with play therapy (P-OST); (2) an educational support intervention (EST); and (3) a 6 month waitlist control condition. If children in the EST or waitlist conditions continue to experience their phobia, they will be offered the one session cognitive-behavioural intervention at 12 months follow-up.

  • Think Dental, Be Active!: A randomised control trial using psycho-education, physical activity and oral health interventions in older adults aged >50 years old, residing in Royal Freemason Benevolent Institute residential aged care facilities.

    This study aims to investigate whether a 12-week combined psycho-education, exercise and oral health intervention can improve general wellbeing, cognition, mental and metabolic health in individuals residing in residential aged care. The active intervention will comprise a group-based exercise and psycho-education program with immediate dental treatment. Results will be compared to an active workbook control condition, who will be offered the oral health intervention following the 12-week intervention period. We hypothesise that the combined psycho-education, exercise and oral health intervention can improve general wellbeing, cognition, mental health and metabolic health, and we may see a greater positive effect of the combined exercise and psychoeducation program in the facilitated group as compared to the active workbook control group. Furthermore, we may find that the dental treatment is more effective following the completion of the exercise and psychoeducation program rather than concurrently with the exercise and psychoeducation program.

  • Evaluation of the Cardihab Smartphone Application for the Delivery of Cardiac Rehabilitation

    Cardiovascular disease (CVD) is the leading cause of death in Australia . Cardiac rehabilitation (CR) programs assist recovery after a cardiac event and reduce the risk of repeat events. The uptake of CR programs is as low as 10-30% with a variety of barriers to attendance. Using technology via a smart phone app with a specific cardiac rehabilitation format may assist with overcoming some of these barriers and may be used to enhance program uptake and completion .

  • A Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of JHL1188 versus Herceptin (EU and US sourced) in Healthy Male subjects

    This is a three-arm, pharmacokinetic, safety, tolerability and immunogenicity study to compare investigational product JHL1188 versus EU and US sourced Herceptin in healthy male participants. Who is it for? You may be eligible to join this study if you are male aged 18 to 55 years old, healthy non-smoker and non-drinker Study details Approximately 159 eligible subjects will be randomized in a 1:1 ratio to receive either JHL1188 (n=53), Herceptin_EU sourced (n=64) or Herceptin_US sourced (n=53). Each subject will receive one intravenous (IV) infusions of the investigational product at the dose of 6 mg/kg on Day 1. Assessments of PK, safety, tolerability, immunogenicity will be collected over the following 70-day period. JHl1188 is developed as a biosimilar of Herceptin, Herceptin is approved for the treatment of adult patients with HER2 positive breast cancer and metastatic gastric cancer. This clinical study is intended to study the similarity between JHL1188 and Herceptin.

  • Assessment of neuroinflammation in boxers

    The purpose of the study is to identify the presence of inflammation in the brains of boxers if any, by comparing the PET/MRI images of participants from the boxer group to the ones from the non-boxing control group and MS patients (positive control group). To do this, the trial will quantify the uptake of the PET tracer [18F]PBR111 as an indicator of neuroinflammation in the three groups. Having this kind of advanced brain imaging available in Brisbane could become very important for monitoring the brain health not just of boxers, but also players in many other contact sports like rugby union or rugby league. Most importantly, this research may serve as a strong background in future PET studies of brain inflammation in cases of AD, MS and other brain disorders.

  • Australian lifestyle change program to prevent or delay type 2 diabetes (AUS2PREVENT)

    The Australian Type 2 Diabetes Prevention Program (AUS 2 Prevent) is a year-long lifestyle change program comprising physical activity and diet sessions. It is a community-based program that aim to prevent or delay diabetes incidence in adults at high risk of developing type 2 diabetes in Australian community. We hope this program will be an effective, feasible and acceptable diabetes prevention program in the Australian community. We are in the process of analysis the data and the final publications should be ready by early 2026.

  • Feasibility of the Cochlear™ Nucleus® Cochlear Implant in a Newly Implanted Adult Population

    The purpose of the feasibility study is to examine speech perception outcomes (quiet and noise) and safety (adverse events and adverse device effects) with the cochlear implant in eleven newly implanted adults who meet the eligibility criteria for the study.

Tags:
  • Finding clinical trials